Avalyn Pharma (NASDAQ:AVLN) Cut to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Avalyn Pharma from “hold” to “sell,” while analyst sentiment overall remains a “Moderate Buy” with an average $60 price target.
• Brokerage opinions are mixed: Jefferies, Guggenheim, and Evercore issued bullish ratings with price targets ranging from $51 to $80, while Weiss Ratings assigned a “sell (D+)” rating.
• Avalyn Pharma shares recently rose 7.3% to $39.25, near their 12-month high, and the company reported a quarterly loss of $0.98 per share—better than the expected $1.03 loss.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

A number of other brokerages have also issued reports on AVLN. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a research report on Thursday. They set a "sell (d+)" rating on the stock. Jefferies Financial Group assumed coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a "buy" rating and a $52.00 price target for the company. Guggenheim began coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They issued a "buy" rating and a $80.00 price target on the stock. Evercore initiated coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They set an "outperform" rating and a $51.00 price objective on the stock. Finally, Zacks Research raised shares of Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $60.00.

Avalyn Pharma Stock Up 7.3%

AVLN opened at $39.25 on Friday. The firm has a market cap of $1.74 billion and a price-to-earnings ratio of -1.80. The firm has a 50 day simple moving average of $30.15. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 11.03. Avalyn Pharma has a 12-month low of $24.15 and a 12-month high of $39.99.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.03) by $0.05. As a group, analysts anticipate that Avalyn Pharma will post -3.81 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Avalyn Pharma stock. Bank of New York Mellon Corp bought a new position in Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 40,140 shares of the company's stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned 0.09% of Avalyn Pharma at the end of the most recent reporting period.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source